Telix Pharmaceuticals Ltd. (TLX)
11.02
-0.10
(-0.90%)
USD |
NASDAQ |
Oct 08, 16:00
11.02
0.00 (0.00%)
After-Hours: 18:05
Telix Pharmaceuticals Enterprise Value : 3.711B for Oct. 7, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 07, 2026 | 3.711B |
| October 06, 2026 | 3.595B |
| October 05, 2026 | 3.629B |
| October 02, 2026 | 3.517B |
| October 01, 2026 | 3.575B |
| September 30, 2026 | 3.660B |
| September 29, 2026 | 3.786B |
| September 28, 2026 | 3.881B |
| September 25, 2026 | 3.823B |
| September 24, 2026 | 3.775B |
| September 23, 2026 | 3.762B |
| September 22, 2026 | 3.993B |
| September 21, 2026 | 3.775B |
| September 18, 2026 | 4.210B |
| September 17, 2026 | 4.181B |
| September 16, 2026 | 3.952B |
| September 15, 2026 | 4.292B |
| September 14, 2026 | 3.935B |
| September 11, 2026 | 3.769B |
| September 10, 2026 | 3.976B |
| September 09, 2026 | 4.125B |
| September 08, 2026 | 4.003B |
| September 04, 2026 | 3.989B |
| September 03, 2026 | 3.921B |
| September 02, 2026 | 3.823B |
| Date | Value |
|---|---|
| September 01, 2026 | 3.619B |
| August 31, 2026 | 3.701B |
| August 28, 2026 | 3.769B |
| August 27, 2026 | 3.797B |
| August 26, 2026 | 3.714B |
| August 25, 2026 | 3.904B |
| August 24, 2026 | 3.901B |
| August 21, 2026 | 3.782B |
| August 20, 2026 | 4.153B |
| August 19, 2026 | 4.051B |
| August 18, 2026 | 3.969B |
| August 17, 2026 | 3.918B |
| August 14, 2026 | 3.949B |
| August 13, 2026 | 4.122B |
| August 12, 2026 | 4.000B |
| August 11, 2026 | 4.010B |
| August 10, 2026 | 3.938B |
| August 07, 2026 | 3.847B |
| August 06, 2026 | 3.548B |
| August 05, 2026 | 3.473B |
| August 04, 2026 | 3.429B |
| August 03, 2026 | 3.337B |
| July 31, 2026 | 3.293B |
| July 30, 2026 | 3.351B |
| July 29, 2026 | 3.364B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Mesoblast Ltd. | 1.853B |
| Immutep Ltd. | -- |
| CSL Ltd. | -- |
| Ceryvyn Therapeutics Ltd. | -- |
| Propanc Biopharma, Inc. | 1.328M |
Enterprise Value Related Metrics
| Earnings Yield | 0.85% |
| Normalized Earnings Yield | 0.4955 |